Sponsor:
MedSIR
Code:
NCT06172127
Conditions
HER2-positive Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Trastuzumab deruxtecan
Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-14. This information was provided to ClinicalTrials.gov by MedSIR on 2025-07-29.